new-drug-for-parkinsons

New drug may offer relief for movement difficulties in Parkinson’s disease

An experimental drug – known as opicapone – is showing promise in improving movement difficulties experienced in Parkinson’s disease. When taken alongside standard treatment (levodopa), the drug has been shown to help improve movement.

Researchers found that opicapone helps boost levodopa’s ability to control Parkinson-induced motor difficulties in patients. These difficulties include tremors, stiffness, and slowed movements.

There is currently no cure for Parkinson’s disease and so far there isn’t a treatment that can slow down the disease progression. On the other hand, certain medications have been found to help improve movement problems.

Motor problems arise in Parkinson’s disease as a result of decreased dopamine levels. The drug levodopa targets the central nervous system and is converted into dopamine by the brain. Levodopa is the first line of treatment for Parkinson’s disease because of its benefits in controlling movement problems in patients.

Unfortunately, levodopa medications are associated with unwanted side effects such as severe nausea. For this reason, levodopa must be taken with carbidopa to prevent nausea. In addition, patients who have been taken levodopa for a while usually experience a wearing-off effect characterized by involuntary movement.

In order to test the new drug opicapone, the researchers studied 427 Parkinson’s patients who were experiencing waning effects of levodopa, of which 286 participants completed the study. Researchers found that those taking higher dosages of opicapone experienced significant reduction in the amount which levodopa failed to work. This was not seen among those taking lower dosages.

Dr. Allison Boyle and her team wrote in an accompanying editorial, “This study … found opicapone to be safe, well tolerated, and easy to dose. Once-a-day opicapone therapy could result in an easier and practical treatment approach for patients and clinicians.”


Author Bio

Mohan Garikiparithi got his degree in medicine from Osmania University (University of Health Sciences). He practiced clinical medicine for over a decade before he shifted his focus to the field of health communications. During his active practice he served as the head of the Dept. of Microbiology in a diagnostic centre in India. On a three-year communications program in Germany, Mohan developed a keen interest in German Medicine (Homoeopathy), and other alternative systems of medicine. He now advocates treating different medical conditions without the use of traditional drugs. An ardent squash player, Mohan believes in the importance of fitness and wellness.

Advertisement

https://consumer.healthday.com/cognitive-health-information-26/parkinson-s-news-526/new-parkinson-s-drug-may-combat-movement-difficulties-718345.html

Popular Stories